20240429_TSPC_Laporan Informasi dan Fakta Material_31631340_lamp1.pdf

Under the abovementioned challenging circumstance, PT. Tempo Scan Pacific, Tbk
(Tempo Scan) in 1st Guarter 2024 was able to register a commendable net
sales increase of 6.40 and amounted to Rp.3,441.8 billion, such a result
was driven by its Pharmaceutical and Consumer Products & Cosmetics
(“CPC”) divisions' net sales which respectively grew by 28.1”/o and 11.6Yo,
on the other hand its Distribution division net sales had decreased by 11.6Y4.

Commensurately such Tempo Scan's Pharmaceutical and CPC divisions net sales
growth are the manifestation of its organic business stellar growth, conseguently
Tempo Scan's 1st Guarter 2024 operating profit has jumped by 156.9Yo and
amounted to Rp.537.6 billion, henceforth it delivered a high operating profit
margin of 15.690.

Tempo Scan's 1st Ouarter 2024 aforesaid net sales performance major benefactors
were as follows:

1) Tempo Scan's Pharmaceutical division was able to sustain its net sales
stellar growth which grew high double digits by 28.1”o and amounted
to Rp.1,153.7 billion, such net sales growth was significantly higher when
compared to its growth in the same period last year which was only 5.3Y9.

This division net sales growth main benefactor remained to be its Consumer
Health products group which net sales increased commendably by
28.3Yo and amounted to Rp.1,135.5 billion. This Consumer Health group's
commendable net sales increase was propelled by its Nutritional products' net
sales which has risen exponentially by 51.0”o year on year. The said
Nutritional products rapid sales growth was propelled by such products nationwide
consumers demand substantial increase across all sales channels and geographical
areas including outside Java island.

Such stellar performance was also exhibited by its Consumer Health group's OTC
and Vitamins products which net sales increased commendably by 10.2Y6, such a
net sales growth was significantly better compared to the Indonesian
Pharmaceutical OTC (Branded) market which registered a significant
decline of 3.53Yo in 2023. However, Tempo Scan is not complacent with its
aforesaid net sales robust growth and it anticipates that the abovementioned OTC
market will still face further challenge, since the overall pharmaceutical and
nutritional markets are still undergoing transition phase influenced amongst others
by factors including more stringent regulatory environment. du

Page | 2

2)

Moving on to Tempo Scan Pharmaceutical division's Prescription Medicines group
net sales which increased by 15.6Yo or higher compared to the Indonesian
Pharmaceutical Prescription drugs market which was able to grow by 6.27Y9
(Branded & Unbranded). Henceforth, in 15 Guarter 2024 its net sales amounted to
Rp.18.2 billion. Correspondingly, in 1st Guarter 2024 Tempo Scan's Consumer
Health products group and its Prescription Medicines group net sales contributions
toward its Pharmaceutical division's total net sales were 98.4Yo and 1.6Yo
respectively.

In addition, this Pharmaceutical division's international business net sales had
increased by 13.2Y6 and amounted to Rp.63.5 billion, such net sales growth was
lower compared to its growth in corresponding period last year which was 18.7Yo.
Conseguently, the aforementioned international business net sales contribution
towards Tempo Scan's Pharmaceutical division total net sales was 5.5Y9 or lower
compared to its contribution of 6.2Y6 in corresponding period last year.

Tempo Scan's Consumer Products & Cosmetics (“CPC”) division was able
to register a commendable net sales growth which increase by 11.6Yo
and amounted to Rp.1,084.1 billion. This division's net sales primary
benefactor remained to be its Consumer Products group which net sales increased
commendably by 12.9Yo and amounted to Rp.887.6 billion. While its Cosmetics
group's net sales performance had continued to deliver a positive growth of 6.0Y6
and amounted to Rp.196.5 billion.

The CPC division core brand eguities' products, given their established market
positions, are well poised to face the FMCG market ongoing conundrum, that is
related to the market dynamic wherein FMCG products substantial price increase
opportunity will gradually diminish in 2024, whilst many major companies
competing in this space have opted to take price cuts in order to halt their products
declining sales.

Conseguently, the aforementioned Consumer Products group and Cosmetics group
net sales contributions toward Tempo Scan's CPC division's total net sales were
81.9Yo and 18.1Y6 respectively in 1st Ouarter 2024, such a contribution was
marginally changed when compared to these net sales contributions the same
period last year which were at 80.9Y6 and 19.1Yo respectively.

For 1st Ouarter 2024, the CPC division's International Business net sales was able
to sustained its stellar growth and registered a commendable double-digit net sales
increase of 22.8Yo. Such a strong net sales performance was contributed by
its Consumer Products and Cosmetics which net sales have increased by
15.1Yo and 24.8Yo respectively. Conseguently, this International Business net
sales contribution towards the CPC division's total net sales had increased to
become 4.496 versus its contribution in 15 Guarter 2023 which was stood at 4.0Y0.

tw

Page | 3

3) Tempo Scan's Distribution division net sales decreased by 11.6Yo and amounted to
Rp.1,203.9 billion. Its main contributor of this division net sales growth was its Non-
Pharma Principals' products which net sales decreased by 13.4Y6 and amounted to
Rp.1,102.8 billion, while on the other hand this division Pharma Principals' products
registered an increase of 15.16 and amounted to Rp.101.1 billion.
Correspondingly, the aforesaid Non-Pharma Principals' products and Pharma
Principals' products net sales contributions toward the Distribution division total net
sales stood at 91.6Y6 and 8.4Y4 respectively.

Furthermore, in 1st Guarter 2024 Tempo Scan's gross profit result registered a
significant increase of 14.5/o and amounted to Rp.1,264.7 billion, such an
increase was significantly higher compared to its net sales growth rate, conseguently
its gross profit margin had increased to become 36.70 versus its gross
profit margin in the corresponding period last year which was 34.2Yo.

The said gross profit margin result is amongst the highest that Tempo Scan has ever
achieved in the past decade. And such a gross profit margin robust performance was
primarily attributed to its business mix change whereas Tempo Scan Pharmaceutical
and CPC divisions net sales have risen considerably and these businesses generated
significantly higher gross profit margin vis-a-vis its Distribution division which net sales
has declined and with lower gross profit margin.

Moreover, the said gross profit margin substantial increase was also attributed by its
key raw materials prices declined in line with the global commodity prices downward
trend. Moreover, commencing in the beginning of 2023 Tempo Scan has commenced
commercial production of its dairy spray drying manufacturing facility, such a facility
substitutes Tempo Scan's base powder milk which was previously imported, therefore
such a facility has reduced considerably its nutritional products' cost of goods sold.

Moving on to Tempo Scan's total operating expenses in 1st Ouarter 2024 decreased
by 18.8Yo and amounted to Rp.727.2 billion, such a decrease was contributed amongst
others by its total selling expenses that had decreased by 1.3Yo and amounted to
Rp.645.8 billion. Conseguently, this total selling expenses as a ratio to Tempo Scan's
consolidated net sales was 18.8Yo or lower compared to the same period last year
whereas such ratio was 20.2Yo.

On the other hand, its total general administrative expenses increased by 20.4Yo and
amounted to Rp.166.8 billion which was due to earlier payment disbursement of
special mandatory bonus (“THR”) prior to Eid Al-Fitr period, hence the said total
general administrative expenses ratio towards Tempo Scan's consolidated net sales
was 4.8Yo or higher compared to the ratio in the same period last year which was

4.3Yo.
Yw

Page | 4

Moreover, its other operating income/(expenses) which net amount was positive by
Rp.85.3 billion as such it was a sharp contrast compared to its other operating
income/(expenses) net amount that was negative by Rp.103.4 billion in 15" Guarter
2023. The abovementioned a net positive amount was mainly caused by its foreign
exchange (forex) gain which amounted to Rp.54.8 billion in 1st Guarter 2024 as
opposed to its unrealized foreign exchange losses that amounted to Rp.109.7 billion
in 1st Guarter 2023.

Notwithstanding the above, Tempo Scan's operating profit in 1st Guarter 2024
managed to register meteoric rise of 156.9/o and amounted to Rp.537.6
billion, hence its operating profit margin stood at 15.6Yo or a sharp increase
versus its operating margin of 6.5Yo in the corresponding period last year.
Such a record operating profit margin was amongst the highest that Tempo Scan had
ever achieved in the last decade.

Furthermore, its 1st Ouarter 2024 net non-operating income had decreased and
amounted to Rp.24.9 billion or lower compared to corresponding period last year
which amount was Rp.489.4 billion. This decrease was mainly attributed to the one-
time gain obtained in 1st Guarter 2023. As the result, Tempo Scan's 1st Guarter
2024 net profit after tax has decreased by 28.4Yo and amounted to
Rp.407.4 billion, conseguently its net profit after tax margin stood at 11.8Yo or lower
versus its net profit after tax margin in the same period previous year which was
17.696, it is worth reiterating that Tempo Scan 1st Guarter 2023 high net
profit after tax was attributed to a non-recurring and non-operating
income, whilst its net profit after tax in 1st Guarter 2024 was the resultant
of its recurring and organic income.

Correspondingly to the above, Tempo Scan's EBITDA has significantly risen by
114.200 and amounted to Rp.623.1 billion, hence its EBITDA margin in
1st Ouarter 2024 stood at 18.1”o or higher compared to its EBITDA margin
in previous year which was at 9.0Yo.

As pertained to Tempo Scan's balance sheet position as of 31 March 2024, it remained
solid whereas its cash and cash eguivalent position total amount stood at Rp.3,901.4
billion or an increase of 7.4Yo compared to corresponding period last year. In addition,
its net operating cycle was at 65 days despite the challenging market condition. Lastly
Tempo's Scan total assets and shareholders' eguity were amounted to Rp.11,929.9
billion and Rp.8,514.7 billion respectively.

Page | 5

Tempo Scan's Board of Directors would like to express our highest appreciation to all
Tempo Scan's Board Commissioners, its management team and all of its employees
for their continuous support, advise, dedication, commitment and hard works as well
as to our valued shareholders, business partners, vendors, customers and professional
parties.

Jakarta, 30 April 2024
On behalf of PT. Tempo Scan Pacific, Tbk.

—

I Made Dharma Wijaya
President Director

Copies:
- Mr. Handojo S. Muljadi, Tempo Scan's Executive Chairman
- Tempo Scan's Board of Directors

Page | 6